BioWorld

Oct. 31, 2002

Inspire Says INS365 NDA Filing Not Far Off; Stock Jumps 53%

Inspire Pharmaceuticals Inc. said following a productive meeting with the FDA, it has decided to compile existing data from three trials of its dry-eye product, INS365 Ophthalmic, and submit it for regulatory approval. (BioWorld Today) Read More

Patience Is Secret Of Herpes Virus Long-Term Latency Strategy, Not Molecular Maneuverings In People

Neurogenetics Closes Series B With Second Tranche Of $10M

Other News To Note

Correction

Serono, IVAX Sign To Develop Cladribine As Oral MS Treatment

U.S. Patent Disclosures

Kemia Closes Potential $16.5M Series A To Fund Clinical Trials

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...